| |
Public Act 099-0711 Public Act 0711 99TH GENERAL ASSEMBLY |
Public Act 099-0711 | HB4462 Enrolled | LRB099 16680 NHT 41018 b |
|
| AN ACT concerning public health.
| Be it enacted by the People of the State of Illinois,
| represented in the General Assembly:
| Section 1. Short title. This Act may be cited as the | Epinephrine Auto-Injector Act. | Section 5. Definitions. As used in this Act: | "Administer" means to directly apply an epinephrine | auto-injector to the body of an individual. | "Authorized entity" means any entity or organization, | other than a school covered under Section 22-30 of the School | Code, in connection with or at which allergens capable of | causing anaphylaxis may be present, including, but not limited | to, independent contractors who provide student transportation | to schools, recreation camps, colleges and universities, day | care facilities, youth sports leagues, amusement parks, | restaurants, sports arenas, and places of employment. The | Department shall, by rule, determine what constitutes a day | care facility under this definition. | "Department" means the Department of Public Health. | "Epinephrine auto-injector" means a single-use device used | for the automatic injection of a pre-measured dose of | epinephrine into the human body. | "Health care practitioner" means a physician licensed to |
| practice medicine in all its branches under the Medical | Practice Act of 1987, a physician assistant under the Physician | Assistant Practice Act of 1987 with prescriptive authority, or | an advanced practice nurse with prescribing authority under | Article 65 of the Nurse Practice Act. | "Pharmacist" has the meaning given to that term under | subsection (k-5) of Section 3 of the Pharmacy Practice Act. | "Undesignated epinephrine auto-injector" means an | epinephrine auto-injector prescribed in the name of an | authorized entity. | Section 10. Prescription to authorized entity; use; | training. | (a) A health care practitioner may prescribe epinephrine | auto-injectors in the name of an authorized entity for use in | accordance with this Act, and pharmacists and health care | practitioners may dispense epinephrine auto-injectors pursuant | to a prescription issued in the name of an authorized entity. | Such prescriptions shall be valid for a period of 2 years. | (b) An authorized entity may acquire and stock a supply of | undesignated epinephrine auto-injectors pursuant to a | prescription issued under subsection (a) of this Section. Such | undesignated epinephrine auto-injectors shall be stored in a | location readily accessible in an emergency and in accordance | with the instructions for use of the epinephrine | auto-injectors. The Department may establish any additional |
| requirements an authorized entity must follow under this Act. | (c) An employee or agent of an authorized entity or other | individual who has completed training under subsection (d) of | this Section may: | (1) provide an epinephrine auto-injector to any | individual on the property of the authorized entity whom | the employee, agent, or other individual believes in good | faith is experiencing anaphylaxis, or to the parent, | guardian, or caregiver of such individual, for immediate | administration, regardless of whether the individual has a | prescription for an epinephrine auto-injector or has | previously been diagnosed with an allergy; or | (2) administer an epinephrine auto-injector to any | individual on the property of the authorized entity whom | the employee, agent, or other individual believes in good | faith is experiencing anaphylaxis, regardless of whether | the individual has a prescription for an epinephrine | auto-injector or has previously been diagnosed with an | allergy. | (d) An employee, agent, or other individual authorized must | complete an anaphylaxis training program before he or she is | able to provide or administer an epinephrine auto-injector | under this Section. Such training shall be valid for a period | of 2 years and shall be conducted by a nationally recognized | organization experienced in training laypersons in emergency | health treatment. The Department shall include links to |
| training providers' websites on its website. | Training shall include, but is not limited to: | (1) how to recognize signs and symptoms of an allergic | reaction, including anaphylaxis; | (2) how to administer an epinephrine auto-injector; | and | (3) a test demonstrating competency of the knowledge | required to recognize anaphylaxis and administer an | epinephrine auto-injector. | Training may also include, but is not limited to: | (A) a review of high-risk areas on the authorized | entity's property and its related facilities; | (B) steps to take to prevent exposure to allergens; | (C) emergency follow-up procedures; and | (D) other criteria as determined in rules adopted | pursuant to this Act. | Training may be conducted either online or in person. The | Department shall approve training programs and list permitted | training programs on the Department's Internet website. | Section 15. Costs. Whichever entity initiates the process | of obtaining undesignated epinephrine auto-injectors and | providing training to personnel for carrying and administering | undesignated epinephrine auto-injectors shall pay for the | costs of the undesignated epinephrine auto-injectors. |
| Section 20. Limitations. The use of an undesignated | epinephrine auto-injector in accordance with the requirements | of this Act does not constitute the practice of medicine or any | other profession that requires medical licensure. | Nothing in this Act shall limit the amount of epinephrine | auto-injectors that an authorized entity or individual may | carry or maintain a supply of. | Section 85. Rulemaking. The Department shall adopt any | rules necessary to implement and administer this Act. | Section 87. The State Police Act is amended by adding | Section 40 as follows: | (20 ILCS 2610/40 new) | Sec. 40. Training; administration of epinephrine. | (a) This Section, along with Section 10.19 of the Illinois | Police Training Act, may be referred to as the Annie LeGere | Law. | (b) For the purposes of this Section, "epinephrine | auto-injector" means a single-use device used for the automatic | injection of a pre-measured dose of epinephrine into the human | body prescribed in the name of the Department. | (c) The Department may conduct or approve a training | program for State Police officers to recognize and respond to | anaphylaxis, including, but not limited to: |
| (1) how to recognize symptoms of an allergic reaction; | (2) how to respond to an emergency involving an | allergic reaction; | (3) how to administer an epinephrine auto-injector; | (4) how to respond to an individual with a known | allergy as well as an individual with a previously unknown | allergy; | (5) a test demonstrating competency of the knowledge | required to recognize anaphylaxis and administer an | epinephrine auto-injector; and | (6) other criteria as determined in rules adopted by | the Department. | (d) The Department may authorize a State Police officer who | has completed the training program under subsection (c) to | carry, administer, or assist with the administration of | epinephrine auto-injectors whenever he or she is performing | official duties. | (e) The Department must establish a written policy to | control the acquisition, storage, transportation, | administration, and disposal of epinephrine auto-injectors | before it allows any State Police officer to carry and | administer epinephrine auto-injectors. | (f) A physician, physician's assistant with prescriptive | authority, or advanced practice registered nurse with | prescriptive authority may provide a standing protocol or | prescription for epinephrine auto-injectors in the name of the |
| Department to be maintained for use when necessary. | (g) When a State Police officer administers epinephrine | auto-injector in good faith, the officer and the Department, | and its employees and agents, incur no liability, except for | willful and wanton conduct, as a result of any injury or death | arising from the use of an epinephrine auto-injector. | Section 88. The Illinois Police Training Act is amended by | adding Section 10.19 as follows: | (50 ILCS 705/10.19 new) | Sec. 10.19. Training; administration of epinephrine. | (a) This Section, along with Section 40 of the State Police | Act, may be referred to as the Annie LeGere Law. | (b) For purposes of this Section, "epinephrine | auto-injector" means a single-use device used for the automatic | injection of a pre-measured dose of epinephrine into the human | body prescribed in the name of a local governmental agency. | (c) The Board shall conduct or approve an optional advanced | training program for police officers to recognize and respond | to anaphylaxis, including the administration of an epinephrine | auto-injector. The training must include, but is not limited | to: | (1) how to recognize symptoms of an allergic reaction; | (2) how to respond to an emergency involving an | allergic reaction; |
| (3) how to administer an epinephrine auto-injector; | (4) how to respond to an individual with a known | allergy as well as an individual with a previously unknown | allergy; | (5) a test demonstrating competency of the knowledge | required to recognize anaphylaxis and administer an | epinephrine auto-injector; and | (6) other criteria as determined in rules adopted by | the Board. | (d) A local governmental agency may authorize a police | officer who has completed an optional advanced training program | under subsection (c) to carry, administer, or assist with the | administration of epinephrine auto-injectors provided by the | local governmental agency whenever he or she is performing | official duties. | (e) A local governmental agency that authorizes its | officers to carry and administer epinephrine auto-injectors | under subsection (d) must establish a policy to control the | acquisition, storage, transportation, administration, and | disposal of epinephrine auto-injectors and to provide | continued training in the administration of epinephrine | auto-injectors. | (f) A physician, physician's assistant with prescriptive | authority, or advanced practice registered nurse with | prescriptive authority may provide a standing protocol or | prescription for epinephrine auto-injectors in the name of a |
| local governmental agency to be maintained for use when | necessary. | (g) When a police officer administers an epinephrine | auto-injector in good faith, the police officer and local | governmental agency, and its employees and agents, incur no | liability, except for willful and wanton conduct, as a result | of any injury or death arising from the use of an epinephrine | auto-injector. | Section 90. The School Code is amended by changing Section | 22-30 as follows:
| (105 ILCS 5/22-30)
| Sec. 22-30. Self-administration and self-carry of asthma | medication and epinephrine auto-injectors; administration of | undesignated epinephrine auto-injectors; administration of an | opioid antagonist.
| (a) For the purpose of this Section only, the following | terms shall have the meanings set forth below:
| "Asthma inhaler" means a quick reliever asthma inhaler. | "Epinephrine auto-injector" means a single-use device used | for the automatic injection of a pre-measured dose of | epinephrine into the human body.
| "Asthma medication" means a medicine, prescribed by (i) a | physician
licensed to practice medicine in all its branches,
| (ii) a licensed physician assistant with prescriptive |
| authority, or (iii) a licensed advanced practice
nurse with | prescriptive authority
for a pupil that pertains to the pupil's
| asthma and that has an individual prescription label.
| "Opioid antagonist" means a drug that binds to opioid | receptors and blocks or inhibits the effect of opioids acting | on those receptors, including, but not limited to, naloxone | hydrochloride or any other similarly acting drug approved by | the U.S. Food and Drug Administration. | "School nurse" means a registered nurse working in a school | with or without licensure endorsed in school nursing. | "Self-administration" means a pupil's discretionary use of | his or
her prescribed asthma medication or epinephrine | auto-injector.
| "Self-carry" means a pupil's ability to carry his or her | prescribed asthma medication or epinephrine auto-injector. | "Standing protocol" may be issued by (i) a physician | licensed to practice medicine in all its branches, (ii) a | licensed physician assistant with prescriptive authority, or | (iii) a licensed advanced practice nurse with prescriptive | authority . | "Trained personnel" means any school employee or volunteer | personnel authorized in Sections 10-22.34, 10-22.34a, and | 10-22.34b of this Code who has completed training under | subsection (g) of this Section to recognize and respond to | anaphylaxis. | "Undesignated epinephrine auto-injector" means an |
| epinephrine auto-injector prescribed in the name of a school | district, public school, or nonpublic school. | (b) A school, whether public or nonpublic, must permit the
| self-administration and self-carry of asthma
medication by a | pupil with asthma or the self-administration and self-carry of | an epinephrine auto-injector by a pupil, provided that:
| (1) the parents or
guardians of the pupil provide to | the school (i) written
authorization from the parents or | guardians for (A) the self-administration and self-carry | of asthma medication or (B) the self-carry of asthma | medication or (ii) for (A) the self-administration and | self-carry of an epinephrine auto-injector or (B) the | self-carry of an epinephrine auto-injector, written | authorization from the pupil's physician, physician | assistant, or advanced practice nurse; and
| (2) the
parents or guardians of the pupil provide to | the school (i) the prescription label, which must contain | the name of the asthma medication, the prescribed dosage, | and the time at which or circumstances under which the | asthma medication is to be administered, or (ii) for the | self-administration or self-carry of an epinephrine | auto-injector, a
written
statement from the pupil's | physician, physician assistant, or advanced practice
nurse | containing
the following information:
| (A) the name and purpose of the epinephrine | auto-injector;
|
| (B) the prescribed dosage; and
| (C) the time or times at which or the special | circumstances
under which the epinephrine | auto-injector is to be administered.
| The information provided shall be kept on file in the office of | the school
nurse or,
in the absence of a school nurse, the | school's administrator.
| (b-5) A school district, public school, or nonpublic school | may authorize the provision of a student-specific or | undesignated epinephrine auto-injector to a student or any | personnel authorized under a student's Individual Health Care | Action Plan, Illinois Food Allergy Emergency Action Plan and | Treatment Authorization Form, or plan pursuant to Section 504 | of the federal Rehabilitation Act of 1973 to administer an | epinephrine auto-injector to the student, that meets the | student's prescription on file. | (b-10) The school district, public school, or nonpublic | school may authorize a school nurse or trained personnel to do | the following: (i) provide an undesignated epinephrine | auto-injector to a student for self-administration only or any | personnel authorized under a student's Individual Health Care | Action Plan, Illinois Food Allergy Emergency Action Plan and | Treatment Authorization Form, or plan pursuant to Section 504 | of the federal Rehabilitation Act of 1973 to administer to the | student, that meets the student's prescription on file; (ii) | administer an undesignated epinephrine auto-injector that |
| meets the prescription on file to any student who has an | Individual Health Care Action Plan, Illinois Food Allergy | Emergency Action Plan and Treatment Authorization Form, or plan | pursuant to Section 504 of the federal Rehabilitation Act of | 1973 that authorizes the use of an epinephrine auto-injector; | (iii) administer an undesignated epinephrine auto-injector to | any person that the school nurse or trained personnel in good | faith believes is having an anaphylactic reaction; and (iv) | administer an opioid antagonist to any person that the school | nurse or trained personnel in good faith believes is having an | opioid overdose. | (c) The school district, public school, or nonpublic school | must inform the parents or
guardians of the
pupil, in writing, | that the school district, public school, or nonpublic school | and its
employees and
agents, including a physician, physician | assistant, or advanced practice nurse providing standing | protocol or prescription for school epinephrine | auto-injectors,
are to incur no liability or professional | discipline, except for willful and wanton conduct, as a result
| of any injury arising from the
administration of asthma | medication, an epinephrine auto-injector, or an opioid | antagonist regardless of whether authorization was given by the | pupil's parents or guardians or by the pupil's physician, | physician assistant, or advanced practice nurse. The parents or | guardians
of the pupil must sign a statement acknowledging that | the school district, public school, or nonpublic school and its |
| employees and agents are to incur no liability, except for | willful and wanton
conduct, as a result of any injury arising
| from the
administration of asthma medication, an epinephrine | auto-injector, or an opioid antagonist regardless of whether | authorization was given by the pupil's parents or guardians or | by the pupil's physician, physician assistant, or advanced | practice nurse and that the parents or
guardians must indemnify | and hold harmless the school district, public school, or | nonpublic
school and
its
employees and agents against any | claims, except a claim based on willful and
wanton conduct, | arising out of the
administration of asthma medication, an | epinephrine auto-injector, or an opioid antagonist regardless | of whether authorization was given by the pupil's parents or | guardians or by the pupil's physician, physician assistant, or | advanced practice nurse. | (c-5) When a school nurse or trained personnel administers | an undesignated epinephrine auto-injector to a person whom the | school nurse or trained personnel in good faith believes is | having an anaphylactic reaction , or administers an opioid | antagonist to a person whom the school nurse or trained | personnel in good faith believes is having an opioid overdose, | notwithstanding the lack of notice to the parents or guardians | of the pupil or the absence of the parents or guardians signed | statement acknowledging no liability, except for willful and | wanton conduct, the school district, public school, or | nonpublic school and its employees and agents, and a physician, |
| a physician assistant, or an advanced practice nurse providing | standing protocol or prescription for undesignated epinephrine | auto-injectors, are to incur no liability or professional | discipline, except for willful and wanton conduct, as a result | of any injury arising from the use of an undesignated | epinephrine auto-injector or the use of an opioid antagonist | regardless of whether authorization was given by the pupil's | parents or guardians or by the pupil's physician, physician | assistant, or advanced practice nurse.
| (d) The permission for self-administration and self-carry | of asthma medication or the self-administration and self-carry | of an epinephrine auto-injector is effective
for the school | year for which it is granted and shall be renewed each
| subsequent school year upon fulfillment of the requirements of | this
Section.
| (e) Provided that the requirements of this Section are | fulfilled, a
pupil with asthma may self-administer and | self-carry his or her asthma medication or a pupil may | self-administer and self-carry an epinephrine auto-injector | (i) while in
school, (ii) while at a school-sponsored activity, | (iii) while under the
supervision of
school personnel, or (iv) | before or after normal school activities, such
as while in | before-school or after-school care on school-operated
property | or while being transported on a school bus .
| (e-5) Provided that the requirements of this Section are | fulfilled, a school nurse or trained personnel may administer |
| an undesignated epinephrine auto-injector to any person whom | the school nurse or trained personnel in good faith believes to | be having an anaphylactic reaction (i) while in school, (ii) | while at a school-sponsored activity, (iii) while under the | supervision of school personnel, or (iv) before or after normal | school activities, such
as while in before-school or | after-school care on school-operated property or while being | transported on a school bus . A school nurse or trained | personnel may carry undesignated epinephrine auto-injectors on | his or her person while in school or at a school-sponsored | activity. | (e-10) Provided that the requirements of this Section are | fulfilled, a school nurse or trained personnel may administer | an opioid antagonist to any person whom the school nurse or | trained personnel in good faith believes to be having an opioid | overdose (i) while in school, (ii) while at a school-sponsored | activity, (iii) while under the supervision of school | personnel, or (iv) before or after normal school activities, | such as while in before-school or after-school care on | school-operated property. A school nurse or trained personnel | may carry an opioid antagonist on their person while in school | or at a school-sponsored activity. | (f) The school district, public school, or nonpublic school | may maintain a supply of undesignated epinephrine | auto-injectors in any secure location that is accessible | before, during, and after school where an allergic person is |
| most at risk, including, but not limited to, classrooms and | lunchrooms. A physician, a physician assistant who has been | delegated prescriptive authority in accordance with Section | 7.5 of the Physician Assistant Practice Act of 1987, or an | advanced practice nurse who has been delegated prescriptive | authority in accordance with Section 65-40 of the Nurse | Practice Act may prescribe undesignated epinephrine | auto-injectors in the name of the school district, public | school, or nonpublic school to be maintained for use when | necessary. Any supply of epinephrine auto-injectors shall be | maintained in accordance with the manufacturer's instructions. | The school district, public school, or nonpublic school may | maintain a supply of an opioid antagonist in any secure | location where an individual may have an opioid overdose. A | health care professional who has been delegated prescriptive | authority for opioid antagonists in accordance with Section | 5-23 of the Alcoholism and Other Drug Abuse and Dependency Act | may prescribe opioid antagonists in the name of the school | district, public school, or nonpublic school, to be maintained | for use when necessary. Any supply of opioid antagonists shall | be maintained in accordance with the manufacturer's | instructions. | (f-3) Whichever entity initiates the process of obtaining | undesignated epinephrine auto-injectors and providing training | to personnel for carrying and administering undesignated | epinephrine auto-injectors shall pay for the costs of the |
| undesignated epinephrine auto-injectors. | (f-5) Upon any administration of an epinephrine | auto-injector, a school district, public school, or nonpublic | school must immediately activate the EMS system and notify the | student's parent, guardian, or emergency contact, if known. | Upon any administration of an opioid antagonist, a school | district, public school, or nonpublic school must immediately | activate the EMS system and notify the student's parent, | guardian, or emergency contact, if known. | (f-10) Within 24 hours of the administration of an | undesignated epinephrine auto-injector, a school district, | public school, or nonpublic school must notify the physician, | physician assistant, or advanced advance practice nurse who | provided the standing protocol or prescription for the | undesignated epinephrine auto-injector of its use. | Within 24 hours after the administration of an opioid | antagonist, a school district, public school, or nonpublic | school must notify the health care professional who provided | the prescription for the opioid antagonist of its use. | (g) Prior to the administration of an undesignated | epinephrine auto-injector, trained personnel must submit to | their his or her school's administration proof of completion of | a training curriculum to recognize and respond to anaphylaxis | that meets the requirements of subsection (h) of this Section. | Training must be completed annually. Trained personnel must | also submit to his or her school's administration proof of |
| cardiopulmonary resuscitation and automated external | defibrillator certification. The school district, public | school, or nonpublic school must maintain records related to | the training curriculum and trained personnel. | Prior to the administration of an opioid antagonist, | trained personnel must submit to their school's administration | proof of completion of a training curriculum to recognize and | respond to an opioid overdose, which curriculum must meet the | requirements of subsection (h-5) of this Section. Training must | be completed annually. Trained personnel must also submit to | the school's administration proof of cardiopulmonary | resuscitation and automated external defibrillator | certification. The school district, public school, or | nonpublic school must maintain records relating to the training | curriculum and the trained personnel. | (h) A training curriculum to recognize and respond to | anaphylaxis, including the administration of an undesignated | epinephrine auto-injector, may be conducted online or in | person. | Training shall include, but is not limited to: | (1) how to recognize signs and symptoms of an allergic | reaction, including anaphylaxis; | (2) how to administer an epinephrine auto-injector; | and | (3) a test demonstrating competency of the knowledge | required to recognize anaphylaxis and administer an |
| epinephrine auto-injector. | Training may also include, but is not limited to: | (A) a review of high-risk areas within a school and its | related facilities; | (B) steps to take to prevent exposure to allergens; | (C) emergency follow-up procedures; | (D) how to respond to a student with a known allergy, | as well as a student with a previously unknown allergy; and | (E) other criteria as determined in rules adopted | pursuant to this Section. It must include, but is not | limited to: | (1) how to recognize symptoms of an allergic reaction; | (2) a review of high-risk areas within the school and | its related facilities; | (3) steps to take to prevent exposure to allergens; | (4) how to respond to an emergency involving an | allergic reaction; | (5) how to administer an epinephrine auto-injector; | (6) how to respond to a student with a known allergy as | well as a student with a previously unknown allergy; | (7) a test demonstrating competency of the knowledge | required to recognize anaphylaxis and administer an | epinephrine auto-injector; and | (8) other criteria as determined in rules adopted | pursuant to this Section. | In consultation with statewide professional organizations |
| representing physicians licensed to practice medicine in all of | its branches, registered nurses, and school nurses, the State | Board of Education shall make available resource materials | consistent with criteria in this subsection (h) for educating | trained personnel to recognize and respond to anaphylaxis. The | State Board may take into consideration the curriculum on this | subject developed by other states, as well as any other | curricular materials suggested by medical experts and other | groups that work on life-threatening allergy issues. The State | Board is not required to create new resource materials. The | State Board shall make these resource materials available on | its Internet website. | (h-5) A training curriculum to recognize and respond to an | opioid overdose, including the administration of an opioid | antagonist, may be conducted online or in person. The training | must comply with any training requirements under Section 5-23 | of the Alcoholism and Other Drug Abuse and Dependency Act and | the corresponding rules. It must include, but is not limited | to: | (1) how to recognize symptoms of an opioid overdose; | (2) information on drug overdose prevention and | recognition; | (3) how to perform rescue breathing and resuscitation; | (4) how to respond to an emergency involving an opioid | overdose; | (5) opioid antagonist dosage and administration; |
| (6) the importance of calling 911; | (7) care for the overdose victim after administration | of the overdose antagonist; | (8) a test demonstrating competency of the knowledge | required to recognize an opioid overdose and administer a | dose of an opioid antagonist; and | (9) other criteria as determined in rules adopted | pursuant to this Section. | (i) Within 3 days after the administration of an | undesignated epinephrine auto-injector by a school nurse, | trained personnel, or a student at a school or school-sponsored | activity, the school must report to the State Board of | Education in a form and manner prescribed by the State Board | the following information: | (1) age and type of person receiving epinephrine | (student, staff, visitor); | (2) any previously known diagnosis of a severe allergy; | (3) trigger that precipitated allergic episode; | (4) location where symptoms developed; | (5) number of doses administered; | (6) type of person administering epinephrine (school | nurse, trained personnel, student); and | (7) any other information required by the State Board. | If a school district, public school, or nonpublic school | maintains or has an independent contractor providing | transportation to students who maintains a supply of |
| undesignated epinephrine auto-injectors, then the school | district, public school, or nonpublic school must report that | information to the State Board of Education upon adoption or | change of the policy of the school district, public school, | nonpublic school, or independent contractor, in a manner as | prescribed by the State Board. The report must include the | number of undesignated epinephrine auto-injectors in supply. | (i-5) Within 3 days after the administration of an opioid | antagonist by a school nurse or trained personnel, the school | must report to the State Board, in a form and manner prescribed | by the State Board, the following information: | (1) the age and type of person receiving the opioid | antagonist (student, staff, or visitor); | (2) the location where symptoms developed; | (3) the type of person administering the opioid | antagonist (school nurse or trained personnel); and | (4) any other information required by the State Board. | (j) By October 1, 2015 and every year thereafter, the State | Board of Education shall submit a report to the General | Assembly identifying the frequency and circumstances of | epinephrine administration during the preceding academic year. | Beginning with the 2017 report, the report shall also contain | information on which school districts, public schools, and | nonpublic schools maintain or have independent contractors | providing transportation to students who maintain a supply of | undesignated epinephrine auto-injectors. This report shall be |
| published on the State Board's Internet website on the date the | report is delivered to the General Assembly. | On or before October 1, 2016 and every year thereafter, the | State Board shall submit a report to the General Assembly and | the Department of Public Health identifying the frequency and | circumstances of opioid antagonist administration during the | preceding academic year. This report shall be published on the | State Board's Internet website on the date the report is | delivered to the General Assembly. | (k) The State Board of Education may adopt rules necessary | to implement this Section. | (l) Nothing in this Section shall limit the amount of | epinephrine auto-injectors that any type of school or student | may carry or maintain a supply of. | (Source: P.A. 98-795, eff. 8-1-14; 99-173, eff. 7-29-15; | 99-480, eff. 9-9-15; revised 10-13-15.)
| Section 95. The Illinois Food, Drug and Cosmetic Act is | amended by changing Section 3.21 as follows:
| (410 ILCS 620/3.21) (from Ch. 56 1/2, par. 503.21)
| Sec. 3.21. Except as authorized by this Act, the Illinois | Controlled Substances
Act, the Pharmacy Practice Act, the | Dental Practice Act, the Medical
Practice Act of 1987, the | Veterinary Medicine and Surgery Practice Act of
2004, the | Podiatric Medical Practice Act of 1987, or Section 22-30 of the |
| School Code, Section 40 of the State Police Act, Section 10.19 | of the Illinois Police Training Act, or the Epinephrine | Auto-Injector Act, to sell or dispense a
prescription drug | without a prescription.
| (Source: P.A. 99-78, eff. 7-20-15.)
| Section 100. The State Mandates Act is amended by adding | Section 8.40 as follows: | (30 ILCS 805/8.40 new) | Sec. 8.40. Exempt mandate. Notwithstanding Sections 6 and 8 | of this Act, no reimbursement by the State is required for the | implementation of any mandate created by Section 40 of the | State Police Act and Section 10.19 of the Illinois Police | Training Act. |
Effective Date: 1/1/2017
|
|
|